Therapy‐related acute myeloid leukemia after single‐agent treatment with fludarabine for chronic lymphocytic leukemia | Zendy

Lam Clarence C.K. | Zendy; Ma Edmond S.K. | Zendy; Kwong YokLam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Therapy‐related acute myeloid leukemia after single‐agent treatment with fludarabine for chronic lymphocytic leukemia

Author(s) -

Lam Clarence C.K.,

Ma Edmond S.K.,

Kwong YokLam

Publication year - 2005

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.20340

Subject(s) - fludarabine , medicine , chronic lymphocytic leukemia , myeloid leukemia , purine analogue , leukemia , antimetabolite , pancytopenia , oncology , minimal residual disease , myeloid , immunology , chemotherapy , bone marrow , cyclophosphamide , purine , biology , biochemistry , enzyme

A 70‐year‐old man with B‐cell chronic lymphocytic leukemia (CLL) received single‐agent treatment with the purine analogue fludarabine, which led to complete remission. After 8 years, he presented with pancytopenia. Marrow examination showed acute myeloid leukemia (AML) with trilineage myelodysplasia (MDS). Cytogenetic analysis showed an unbalanced der(1;7)(p10;q10) that resulted effectively in deletion 7q; confirming the diagnosis of therapy‐related AML (t‐AML). No residual CLL was present. Together with previous reports of secondary cancers after fludarabine treatment and the association of monosomy 7/7q‐ with another purine analogue azathioprine, results suggest that t‐AML might develop after fludarabine therapy. Am. J. Hematol. 79:288–290, 2005. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research